Try our Advanced Search for more refined results
Life Sciences - August, 2017
367 articles
- Ex-Pharma Accountant, 2 Others Admit To Insider Trading
- Unclear Grammar Lands AbbVie-Novartis IP Row In Arbitration
- Fed. Circ. Won't Rehear Ax Of Cleveland Clinic Test Patent
- PhRMA Joins Fray In Gilead's 9th Circ. FCA Battle
- Atty Allegedly Caught Stealing Secrets In Medical Device Co.
- Impax Must Pay For GSK Wellbutrin Settlement, Teva Says
- Ariz. AG Sues Insys, Docs Over Fentanyl Spray Marketing
- Mylan, Other Drugmakers Must Pay $67M In Antitrust Suit
- Investigate Gilead Patent Deals, AIDS Activists Urge NY
- Activist Investor Elliott Demands More For Stada Stake
- AbbVie Wins First AndroGel Suit In State Court
- ITC To Probe Microfluidic Chip Imports Accused Of Infringing
- The Psychology Of Hourly Fee Arrangements
- Pfizer, Teva Among Latest Opioid Makers In Mo. Probe
- Pa. Mayor To Sue Pharma Cos. Over Opioid Crisis
- Full Fed. Circ. To Weigh USPTO's Win-Or-Lose Atty Fees Rule
- Uncertainty Remains For Pharma Product Hopping Liability
- Indonesia's Troublesome New Patent Law
- High Court Bristol-Myers Ruling: Direction For State Courts
- Teva Hit With Investor Suit Over $40.5B Actavis Merger
- 4 Fast Facts As FDA Clears 'Historic' Novartis Therapy
- Amarin Calls For ITC Investigation Of Omega-3 Supplements
- FDA Issues Guidance On Real-World Medical Device Data
- Apotex Cleared To Intervene In Eagle's Orphan Drug Suit
- 3rd Circ. Lipitor Ruling Smooths Way In Pay-For-Delay Suits
- Susman Godfrey Seeks To Helm Valeant Insider Trading Suit
- Calif. High Court Affirms Taxing Powers Of Voter Initiatives
- FDA Announces Security Update For St. Jude Pacemakers
- Recent Settlements Suggest Off-Label Cases Aren't Extinct
- New Jury Clears J&J In Rembrandt Contact Lens Patent Row
- Amgen, Sandoz Battle Over High Court's Biosimilar Ruling
- FDA Warning Wire: Stem Cell Clinic Fires Back
- Atty May Need DQ In Insys Bribery Case, Feds Say
- Surgeon Says Bone Drill Loud Enough To Damage Hearing
- Feds Say Shkreli Verdict Is No Escape For Ex-Katten Atty
- 3rd Circ. Ruling Doesn't Help Intuniv Buyers, Actavis Says
- DC Circ. Backs FDA's Approval Of Abilify Maintena Rival
- Express Scripts, Others Face ERISA Suit Over EpiPen Costs
- Roche Seeks NJ High Court Review Of Accutane Expert Ruling
- Rockwell Slams Claims It's Mistreating Activist's Director
- Dr. Reddy's Hid Manufacturing Woes, Investors Say
- Hedge Fund Appeals Shareholder Tax Form Decision
- CVS Board Ignored Overbilling Scheme, Shareholder Suit Says
- How Courts Treat USPTO Subject Matter Eligibility Guidelines
- Experts Must Investigate Materials They Rely On
- Provigil Buyers Lose Cert. In Pay-For-Delay Suit
- Greenberg Traurig Forgery Case Stayed For Damages Appeal
- Herbalife Products Damaged Liver, Suit Says
- Lilly Loses Bid To Escape $20M Cialis Patent Verdict
- Consumers Seek J&J Docs In Contact Lens Antitrust MDL
- FDA Drubs Stem Cell Clinics Using Unapproved Treatments
- $235M Patent Award Spurs Teva Redo Request, GSK Fees Bid
- Medical Co. In FCA Case Looks To Dodge Retaliation Claims
- Self-Collection In E-Discovery — Risks Vs. Rewards
- Gilead Sciences Inks $11.9B Deal For Kite Pharma
- Robinson Calcagnie, Smith Law Team Up To Take Down J&J
- FCA Decision Tracker: Continued Interpretations Of Escobar
- RoxyBond Rival Can't Use Suit To Delay Sales, FDA Says
- Trustee Must Face Claims In Genaera Class Action: 3rd Circ.
- Real Estate Rumors: Brookfield, MDN, Brandywine
- Fed. Circ. Affirms PTAB Nix Of Shoulder Implant Patent
- 10th Circ. Affirms Toss Of Faulty Surgical Mesh Claims
- Health Hires: Biopharma GCs, BigLaw Partners, US Prosecutor
- Examining FDA Reauthorization Act Add-On Provisions
- NYC Pharmacist Charged With Medicaid Fraud
- Foreign Discovery Mostly Denied In Zofran Birth Defect MDL
- 6 Common Lateral Partner Myths Debunked
- Del. ANDA Venue Fights Arise After TC Heartland
- 7th Circ. Says Rejected Deal Doesn't Moot False Ad Suit
- BioScrip Investors Urge Del. Justices To Revive Lawsuit
- Pharmaceutical Co. Urges 1st Circ. To Uphold PCB Suit Toss
- St. Jude Must Face Man's Defective Defibrillator Wire Suit
- Cherokee Nation Wants Takeda Actos Suit To Stay In La.
- Impax Can't Bar Goodwin Procter In Teva Coverage Fight
- Roche Appeals Accutane Label Ruling To NJ High Court
- 4 Ways Law Firms Can Help Battle Addiction
- Maine Birth Law Bars Faulty Merck Implant Suit, Judge Says
- InvaGen Infringed Diabetes Drug Patent, Pharma Cos. Say
- W. Va. Doc Gets 20 Years For Pain Prescription Abuses
- IRS Says Agent Depositions Irrelevant To CEO's Penalty Suit
- Costco, NBTY Escape Supplement Label Class Action
- ITT Wins Coverage In Asbestos Insurance Trial
- Fresenius Seeks To Shed 10 More Suits From Dialysis MDL
- Globus Defeats Securities Class Action At 3rd Circ.
- Consumers Ask 2nd Circ. To Revive 'Organic' Baby Food Suit
- Sex-Drug Sellers Settle False Ad Row Over 'Natural' Pills
- A Law Firm Guide To Helping Victims Of Human Trafficking
- Mallinckrodt Defends Hormone Price Hike In Antitrust Suit
- Alere Escapes Most, But Not All, Of Securities Class Action
- Fed. Circ. Resurrects Hindsight Bias In Post-KSR World
- 3 Trial Losses Won't Doom Xarelto Patients
- Discovery Proportionality: A Defense View
- Science No Salve For J&J In Talc Cases, $417M Verdict Shows
- US Bioservices To Settle Kickback Claims For $13.4M
- 'Open Season' For FCA Plaintiffs In 9th Circ., Gilead Says
- Feds Fight To Retry CEO Who Allegedly Gave Info To Ex-MLBer
- FTC, Boehringer Take Last Swipes In Docs Request Appeal
- Generics Makers Beat Reckitt's Mucinex Infringement Claims
- Call Center Worker Hits Drugmaker With OT Class Action
- FDA Warning Wire: Becton Dickinson, Ice Pops, Potent Drugs
- Assessing 'The Value Of Class Actions'
- PTAB Upholds AstraZeneca Diabetes Meds Patent
- 1st Circ. Affirms Dismissal Of Sarepta Securities Suit
- TTAB Says 'Medical Extrusion Technologies' Not Distinctive
- AbbVie, Patient Both Say Jury On Their Side In $150M Award
- EU Watchdog Launches Probe Of $66B Bayer-Monsanto Deal
- Calif. Court OKs Bid For Chinese Co.'s US Assets
- Del. Court Denies Toss Of Tyrogenex Takeover Plot Suit
- Feds Net $12M From Eye Surgery Co. In FCA Kickbacks Deal
- J&J Unit Seeks To Boot Pelvic Mesh Cases From Philly Court
- Krystal Biotech Files $35M IPO Led By Morrison & Foerster
- UHC Ignoring Subpoena In Testosterone MDL, Endo Says
- Pharmacy Seeks Final OK For Roche's $17M TCPA Deal
- Helsinn Redo Request Is Important Opportunity For Fed. Circ.
- Impax Loses Fees Bid In Opioid Pay-For-Delay Row With FTC
- Ex-Katten Atty Says Shkreli Verdict Nixes Conspiracy Count
- Diversity In The Legal Profession — A Stubborn Vision
- Why Midsize Firms Run The Gamut On Diversity
- Law Firms Head Back To School For Diversity Guidance
- GCs Find New Urgency In Longtime Push For Diversity
- Warner Chilcott Must Face Loestrin Pay-For-Delay MDL
- A New Standard For Suspicious Order Monitoring: Part 1
- Pa. Judge Questions Goodwin Procter DQ Bid In Pharma Fight
- 3rd Circ. Revives Lipitor, Effexor Antitrust Claims
- FDA Plans Forum On Opioid Cough Medicines For Children
- Envigo Strikes Latest Deal With A PE-Backed Acquisition Co.
- New Salary History Laws Crimp Attorney Hiring Process
- Son's Wrongful Death Case Not Federal, 11th Circ. Says
- State And Local Tax Scoreboard: 2017 Midyear Review
- Ex-BioChemics CEO's SEC Deal Bars Him From Leading Cos.
- J&J Hit With $417M Verdict In 1st Calif. Talc Cancer Trial
- Endo Misrepresented Opioid Drug Safety, Shareholder Says
- How 5 Firms Are Building More Diverse Ranks
- The Best Firms For Minority Attorneys
- Racial Diversity Stagnating At US Law Firms
- The Top Firms For Minority Equity Partners
- Class Attys Score $44.6M In Fees In $210M Salix Settlement
- Convicted Lawyer Tells High Court Gov't Let Witnesses Lie
- Jury Hands J&J, Bayer Win In 3rd Xarelto Bellwether
- Ex-ArthroCare CEO Convicted Again In $750M Fraud Scheme
- 9th Circ. Partially Revives Securities Suit Against Atossa
- Genentech Beats IP Suit Over Breast Cancer Drug Patent
- Surgery Supply Cos. Slam Bid For Cert in Antitrust Suit
- Apotex Can't Join Nearly Done Orphan Drug Suit, Eagle Says
- Reluctant Judge Approves SEC No-Fault Settlement
- J&J Unit Looks To Block Damages After Pelvic Mesh Win
- Pot Grower Tells Justices 5th Amendment Lets Him Duck Tax
- Enzo DNA Testing Patent Found Invalid In Win For Abbott
- Par Pharmaceutical Beats FCA Prescription-Switch Claims
- Stada Investors OK Sweetened €4.12B Bain, Cinven Buyout
- It's Time For Deal Talks, Attys In Zimmer Knee MDL Told
- FDA Invites Input As Pharma-Ad Overhaul Looms
- US Reps. Probe Bayer, Teva, Novartis On MS Drug Pricing
- Ex-Citigroup Analyst Defeats FINRA Charges Over Tips
- Drugmaker Moves To Stop Natal Vitamin Reclassification
- 5 Tips For A Successful Legal Blog
- Feds Urge Nix Of Ex-Hunton Atty's New Trial, Acquittal Bids
- Grammar May Send AbbVie-Novartis IP Row To Arbitration
- Xarelto Patient Says Jury Can Decide Claims
- Patheon Gets $18.5M Fees After Prevailing In Antitrust Row
- Mylan, Pfizer Escape Suit Over EpiPen Pricing
- Axed 'Short And Smear' Case Shifts To Del. Commercial Court
- Former FTC Litigator Joins Constantine's Antitrust Practice
- Opioid Distributors Facing 10 New Suits In Ala., Ohio
- Wellbutrin Buyers Didn't Show Harm By GSK, 3rd Circ. Says
- FibroGen Prices $326M Follow-On To Fund Cancer Drug
- 'Unhinged' Insider Trading Defendant Pesters Feds Again
- J&J Asks 2nd Circ. To Nix Cert. In 'Natural' Baby Wash Row
- Lateral Surge On The Horizon As BigLaw Gets Into Pot
- Sanofi Blew Whistle On Mylan's EpiPen Rebate Woes: Feds
- Opioid Litigation: What's On The Horizon
- J&J, Woman Spar Over Science At Cancer Trial's Close
- 10th Circ. Ruling Backs Tribal Court In Opioid Suit: Cherokees
- Chinese Co. Must Turn Over US Assets, Calif. Court Hears
- Minn. Justices Say Medtronic Investors Can Sue Over Merger
- Ex-US Atty Joins King & Spalding To Start Chicago Office
- Materia May Be Infringing After $1.5M Verdict, Evonik Says
- Deals Rumor Mill: Teva, Petrobras, Thyssenkrupp
- Judging A Book: Kopf Reviews Posner's 'Federal Judiciary'
- The Proper Measure Of The Value Of Class Actions
- TWi Infringed Supernus Patents For Seizure Drug, Court Says
- The 10 Law Firms Clients Recommend Most
- 3rd Circ. Divides Stryker Poaching Suit Between Calif., NJ
- Investors Seek To Strike Part Of Pershing's Quick Win Bid
- FDA Warning Wire: Another Co. Blasted For Belladonna
- Talc-Cancer Link Is Weak, J&J Expert Says At Trial's End
- Judge Rejects Theranos Investors' Bid To Pause Settlements
- Perrigo Sues IRS For $163M From Drug Sales, Patent Rows
- Judge Denies Consumers Cert. In Celexa, Lexapro MDL
- Ambry Genetics Investors Seek To Block $1B Sale To Konica
- DC Circ. Clears DEA To Block Supplier From Selling Opioids
- Par Pharma Claims Ex-Employees' New Co. Stole Secrets
- Settlement In Place For Herbal Supplement MDL Cases
- Generic Lobby Can't Block Drug Price-Gouging Law, Md. Says
- AFL-CIO Heads Latest To Leave Trump's Job Panel
- The Use Of Special Masters In Complex Cases
- A Plaintiff's Guide To Discovery Proportionality: Part 2
- Notes From A Law Firm Chief Privacy Officer
- No Sign J&J Talc Caused Woman's Cancer, Doc Tells Jury
- Talk Of Deal As Women Ask 2nd Circ. To Revive Mirena MDL
- J&J, Bayer Ask To Strike Doc's Testimony In Xarelto Trial
- IP Trade Association Pushes USTR To Adopt NAFTA Priorities
- Chinese Pharma Co. Gets Nasdaq Leeway Amid FCPA Probe
- CVS, Walgreens Press Bid To Block Cherokee Opioid Suit
- Pa. Judge Explains Call To Keep $2.5M J&J Risperdal Verdict
- FDA's Hatch-Waxman Group To Tackle Wider Generics Issues
- No Cracks In Antitrust Suit Against Biogen, Rival Argues
- A Plaintiff's Guide To Discovery Proportionality: Part 1
- Intel CEO Joins Execs Fleeing Trump Council After Protests
- Notes From A Law Firm Chief Privacy Officer: New Demands
- Del. Case May Set New Roadblocks For 3rd-Party Releases
- Grant & Eisenhofer Claims $7M In Fees Owed From FCA Deal
- Greatbatch-AVX Trial's Willfulness Stage Ends In Hung Jury
- News Outlets Ask Shkreli Trial Judge For Juror Names
- Talc No Cancer Risk, Ex-FDA Scientist Tells J&J Jury
- DaVita Investors Move To Consolidate Derivative Suits
- Mylan Can't Duck Securities Fraud Suit, Investors Say
- Health Hires: CMS Officials Move On To BCBS, PatientPing
- Brand Battles: Uber, Novartis, Coachella, General Motors
- Medical Device Cos. Must Arbitrate IP Dispute, Judge Says
- Escobar Provides New Grounds For Seeking Gov't Discovery
- BioScrip Urges Del. Justices Not To Revive Shareholder Suit
- Fed. Circ. Pushed To Revive $200M Boston Scientific IP Suit
- Thermo Fisher Raises $1.5B Debt To Fund Patheon Acquisition
- What To Know About New FDA Informed Consent Guidance
- It's Time To Improve Voir Dire In Federal Court
- Notes From A Law Firm Chief Privacy Officer: Insider Risks
- Acorda Asks Fed. Circ. To Undo Nix Of Ampyra Drug Patents
- Woman Says Cancer A Surprise After Years Of J&J Talc Use
- Fed. Circ. OKs $12M Fees For Lilly, Elan In IP 'Conspiracy'
- Del. Jury Finds AVX Infringed Greatbatch Device Patent
- Trump To Declare Opioid Crisis A National Emergency
- SEC Fights Broker's Bid To Slip $1.6M Sanofi Fraud Verdict
- Allergan Again Pressures FDA On Restasis Generics
- FDA Says Fla. Pharmacy Is Not Properly Sterilizing Equipment
- Shook Hardy Nabs Life Sciences Trial Pro From Hollingsworth
- AIG, Liberty Say They Don't Have To Cover $11M LabCorp Deal
- Fed. Circ. Snubs Amgen Bid For More Info On Pfizer Biosimilar
- Rising Star: Quinn Emanuel's Laura Fairneny
- 5 Deaths Linked To Obesity Stomach Balloons, FDA Warns
- Notes From A Law Firm Chief Privacy Officer: Balancing Act
- NH, Ore. County Accuse Opioid Makers Of Fueling Crisis
- Shire Beats Contract Suit Seeking $425M From Dry-Eye Drug
- FCPA Prosecutor Returning To Foley & Lardner In DC
- Trade Secrets Victor Had No Part In Tech, Fed. Circ. Told
- What Attys Need To Know About Trump's Opioid Policies
- Mesh Ruling Signals Tough Road For Non-Pa. Cases In Philly
- Humana Beats NJ Specialty Pharmacy's Antitrust Suit
- Dechert Guides Zealand Pharma's Upsized $78M IPO
- ITC Will Probe Hemophilia B Med Patent Infringement Claims
- 3rd Circ. Affirms Win For GSK In Wellbutrin Antitrust Case
- SoftBank Fund Leads $1.1B Equity Investment For Roivant
- Rising Star: Gibson Dunn's Timothy Best
- Deals Rumor Mill: Altice, Teva Pharmaceuticals, Fanatics
- Abuse-Deterrent Opioids Unproven, Unaffordable, Study Says
- Vitamin Shoppe Sued Over Weight Loss Supplement
- Locke Lord Gains London Partner With IP Finesse
- UK Supreme Court Broadens Scope Of Patent Protection
- How The IPad Can Be A Litigator's Best Friend
- Notes From A Law Firm Chief Privacy Officer: CPO Vs. CISO
- Studies Showing No Talc-Cancer Link Are Flawed, Jury Hears
- Athena Diagnostic Test Patent Axed For Covering Natural Law
- Monsanto Reaches Nationwide Roundup False Ad Deal
- Generic Giants Ask Fed. Circ. To Nix Vimpat Patent
- FDA Warning Wire: NYC Embryo Co., Feline Peanut Protector
- Price Hike Not Shkreli's Only Antitrust Woe, Experts Argue
- 9th Circ. Decision Could Be A Bitter Pill For Pharma Cos.
- Mintz Levin Nabs Perkins Coie Patent Atty For NY Office
- Novo Nordisk, Benefits Co. Want Price Hike Fight Sent To NJ
- Rising Star: Hogan Lovells' Adam Bellack
- Apotex Wants In On Orphan Drug Suit To Protect Generic
- Damaged Drug Claims Unsupported, CVS Unit Says
- Pacemaker Co. Wins CIT Suit Over Import Classification
- Industrial Talc Litigation: New Mass Tort Or False Alarm?
- The Rule Of Law Is The Best Medicine: Part 2
- 5 Questions To Ask Before Entering Joint-Representation AFA
- Quinn Emanuel Says Pharma Co. Owes $6M In Back Fees
- Greatbatch, AVX Duel Over Proof And 'Illusion' In IP Trial
- Shkreli's Brazen Defiance May Lead To Harsher Sentence
- Merck Tells Fed. Circ. Antibiotic Obvious Only In 'Hindsight'
- Endo To Pay $775M To End 'Virtually All Known' Mesh Suits
- Fla. Doctor Gets 6 Years For Using Foreign, Unlicensed Drugs
- Monsanto Can Pause Cities' PCBs Suit, Judge Rules
- New FDA Study Supports Simpler Pharma Ads
- Coherus Targets Amgen's Enbrel Patent In IPR
- FDA Says Death Linked To Turmeric IV Product
- K&L Gates Hires Former Sen. Murkowski Staffer As Partner
- FDA Ignoring Abuse-Deterrent Opioid Concerns, Suit Says
- Acorda Therapeutics Slams Investor's Calls To Explore Sale
- Rising Star: Kirkland's Elizabeth Hess
- Fresenius To Buy Home Dialysis Firm NxStage For $2B
- Legal Incubators Can Help New Lawyers And Society
- Metal Fragments In Brain Isn't Injury, 11th Circ. Rules
- BASF Can't Nix NJ Town's Expert In Superfund Site Tax Row
- The Rule Of Law Is The Best Medicine: Part 1
- Talc Use Causes Ovarian Cancer, Calif. Jury Told
- FDA Blocks Utah Outsourcing Co. That Sold Tainted Drugs
- Latest J&J Pelvic Mesh Injury Case Kicks Off In Philly
- Cempra Shareholder Sues Over CEO's Retirement Package
- Miramar Labs Investor Challenges Sientra Deal
- Ultrasound Co. Says Its Arbitral Award Nearly Doubled
- 3 Firms Set To Steer IPOs Totaling $310M Led By Coal Miner
- Taxation With Representation: Debevoise, Weil, Davis, Hogan
- Other Jurisdictions Should Look To 9th Circ.'s Teleflex Ruling
- Rising Star: Axinn Veltrop's Suchira Ghosh
- Shkreli Convicted On 3 Counts In Securities Fraud Trial
- Hedge Funds Sue Teva Over Generic Drug Price-Fixing
- No-Show NYC Pharmacy Loses TCPA Junk Fax Class Action
- A Modern Approach To Digital Health Product Regulation
- The Growing Circuit Split Over FCA First-To-File Rule
- What To Watch As FDA Begins To Fight Rising Drug Prices
- Breaking Down Graham-Cassidy ACA-Replacement Proposal
- PE Firm Wins $87M In Contaminated Heparin Coverage Suit
- Genentech Says IP Suit Should End After Phigenix Attys Leave
- Hurdles Ahead For AbbVie After $150M AndroGel Verdict
- JPML Sends Acid-Reflux Drug Litigation To New Jersey
- Express Scripts Can't Dodge PE Firm's Fraud Suit
- Medical Supplier Wants Abbott Sanctions In Test Strip Suit
- Congress Passes FDA Reauthorization, Approval Reforms
- Israeli Pharma Co. Wants NY Stock-Drop Class Suit Tossed
- Bristol-Myers Squibb: The Aftermath
- Philips Nets Just $7.1M In Defibrillator Infringement Case
- Pa. Court Asked To Revive Actiq Off-Label Marketing Suit
- Troutman Sanders Taps King & Spalding For Atlanta Partner
- 2nd Circ. Affirms Icahn Win Over Short-Swing Trading Suit
- How To Prioritize Your Law Firm's Crisis Response Plan
- Patent Prosecutors Alarmed By Inequitable Conduct Ruling
- Roche May Test Liberal NJ Expert Standard In Accutane Battle
- J&J, DePuy Fight Hip Implant Claims Ahead Of 4th Bellwether
- Ex-Harvard Doc Tells Jury Woman's Ovaries Contained Talc
- Perrigo Gets A Mulligan On $10M IP Verdict Appeal
- Boehringer Biosimilar Flouts 74 Patents, AbbVie Says
- Minn. Justices Nix $1.2M Tax Bill Over Foreign Entity Status
- Texas Court Tosses Suit Over Newborn's Genetic Test
- Ecolab Reaches $6M Wage Settlement With Sales Managers
- Merck Investors' Claims Time-Barred, 3rd Circ. Finds
- Pa. Judge Will Revisit Out-Of-State Cases In Mesh Mass Tort
- DOJ Ramps Up Fight Against Opioid Fraud With 12-Atty Unit
- Judge Tosses Fraud Claims In $2.3B Teva Acquisition Suit
- Fed. Circ. Affirms Axing $61M DNA Patent Win For Yale, Enzo
- Clementia Pharmaceuticals Raises $120M In Upsized IPO
- Oilfield Services Co., Drugmaker Launch IPOs Totaling $160M
- Another Instant Coffee Recalled For Containing Viagra
- KKR, Walgreens Take PharMerica Private In $1.4B Deal
- Zimmer Says Expert Reports Lacking In 95 Knee MDL Cases
- Trimming An MDL Expert's Testimony On Remand
- A Glimpse Into DOJ's New Health Care Enforcement Initiative
- Has Amgen Already Won Its BPCIA Dispute With Sandoz?
- Innovating For Wise Juries: Closing Argument
- Reed Smith Atty's Doctor Knew Of Suicide Risk, GSK Says
- Pharma Co. Won't Get More Time To Keep SEC Registration
- Theranos, Walgreens Settle $140M Contract Suit
- Express Scripts Ducks Stockholder Suit Over Anthem Dispute
- Cleveland Clinic Wants Rehearing Of Heart Test Patent Ax
- Shkreli Jury Asks Judge About 'Fraudulent Intent'
- FTC Shouldn't See Aggrenox Docs, Boehringer Tells DC Circ.
- Express Scripts Will Favor Mylan's EpiPen Over Competitors
- Jefferies Dodges Arbitration With Biotech Investors
- Genetic Medicine Co. Raises $83.5M For Drug Development
- Patent Co. Asks Fed. Circ. To Revive Hip Implant Patent
- Bayer, Monsanto Offer EU Concessions To Clear $66B Deal
- Insurer Fights Covering Negligence Claims In Med Mal Suit
- Medical Co. Owner Charged With Diverting Investor Funds
- An FDA Petition Denial Preempts A Failure-To-Warn Claim
- What's Next For ACA Repeal?
- Daiichi, Forest Reach $300M Settlement In Benicar MDL
- 5 Questions All AFAs Should Answer Clearly